Ratings Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-15 EDT			5-day change	1st Jan Change
3.956 ^USD	+4.09%		+0.78%	+14.65%

05-09	Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XENETIC BIOSCIENCES, INC.	+14.65%	6.09M	-
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B	B+
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B	B+
ARGENX SE	+0.82%	22.27B	B
BIONTECH SE	-12.64%	22.22B	B+
GENMAB A/S	-4.59%	19.43B	A-
WUXI APPTEC CO., LTD.	-37.85%	17.87B	A-
BEIGENE, LTD.	-8.58%	17.24B	B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B	C+
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes